Navigation Links
InstaCare Corp. Reviewing M&A Plans
Date:9/26/2007

Board to Consider Proposals and Variations

LOS ANGELES, Sept. 26 /PRNewswire-FirstCall/-- InstaCare Corp. (OTC Bulletin Board: ISCR) a leading e-health Wi-Fi PDA technology provider, the developer of proprietary technologies for medical DME and EMR applications, and the distributor of life saving prescription drugs, medical diagnostics and medical surgical products, announced today that its Board of Directors will begin review of proposals for possible strategic partnerships and/or merger with several companies with interests in strategic areas related to the company's current businesses. The Board of Directors of InstaCare Corp. will meet within the next week to consider these proposals and other opportunities, some previously discussed, with the singular objective to enhance shareholder value. The Board will also discuss the addition of outside director

InstaCare offers a variety of unique products for medical care and management including diabetes monitoring systems, wound care and ostomy products and more. The Company's innovative technology includes a palm-sized computer allowing physicians to have patients' histories, medication and more at hand. ISCR employs a technology push business model, employing its proprietary technologies to add value to the medical products it distributes.

"As a leader in the development of medical IT solutions, we often receive inquiries from other companies who desire to either enter our fast growing market segments, to bolster existing competitive positions without a need to spend on expensive and lengthy product development projects," commented Keith Berman, InstaCare's CFO "We have a responsibility to consider all opportunities and make the decisions which are in the best interest of our shareholders. The latest opportunities we are considering are intriguing, accretive, and potentially highly enriching."

About InstaCare Corp.

InstaCare Corp. is an emerging fulfillment provider
'/>"/>

SOURCE InstaCare Corp.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Oracle Corp. to help build worlds first "Digital Hospital"
2. FDA To Reconsider Standards for Reviewing Low-Dose Oral Contraceptives
3. France plans to protects its citizens from bird flu
4. MSI puts on hold plans for operations in Chennai
5. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
6. Wockhardt Group Plans Hospital In Delhi By End-2007
7. Alberta’s New Reform Plans In Health Care Secto
8. Blue Cross Signs Up 110,000 Minnesotans For Part D Medicare Plans
9. Little Clinic LLC Plans Super Medical Clinics in Publix Super Markets
10. Medicare Drug Plans Are Onerous and Restrictive
11. Rajasthan Plans To Run Christian Institutions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2008)...ert Pathologists Discuss the Latest Developments i...RTHFIELD, Ill., Sept. 5 /PRNewswire-USNewswire/ --...point. Molecular testing and the promise,of person...reated. Digital,slides and other imaging technolog...lege of American Pathologists is taking a leadersh...
(Date:9/5/2008)...hers explain how theoretical ,anti-cloak, could br...pt. 5 (HealthDay News) -- Just in case someone dev...cientists say they know how to uncloak the objects... Optics Express , certain materials underneath an ...o be seen again. , Researchers at Shanghai Jiao...
(Date:9/5/2008)...HINGTON, Sept. 5 /PRNewswire-USNewswire/ -- Speake...y in support of the aims of the "Stand,Up to Cance... "There is not a person in our country who has no...r kills 565,000 Americans annually, and each,year ...ricans must work,together to make eradicating the ...
(Date:9/5/2008)...HINGTON, Sept. 5 /PRNewswire-USNewswire/ -- U.S. c...r relief to Cuban victims of Hurricane,Gustav, whi...s., (http://www.PanAmericanRelief.org ), "Donatio...perately need,after this natural disaster," says M... Initiative at the Pan American Development Founda...
Breaking Medicine News(10 mins):Health News:Leaders in Pathology Meet in San Diego: Sept. 25 - 28, 2008 2Health News:Cuban Disaster Relief Donations Sought in the Wake of Hurricane Gustav 2
...cancer, constipation and other conditions may soon...f using injections.Scientists in India have develo...s to manage diseases that often require an injecti...nfections. The new gel can also prevent problems c...
...combined efforts to determine the potential health...looked at 20 risk factors.// Some of those include... and hygiene, indoor smoke, childhood sexual abuse...7 percent of premature deaths and 39 percent of to...
...al activity of adults with asthma. Knowing if asth...ing could help health professionals in designing f...the Centers for Disease Control and Prevention con...ctivity levels of adults with asthma. The study in...
..., frequent urination or abnormal periods, uterine ...rous // growths found in the uterus and can range ...e or larger. Now, there’s an improvement to uterin...at’s becoming the procedure of choice for many wom...
Other Medicine News:
(Date:9/4/2008)...o Enroll 750 Women at More Than 100 Sites in the U...atRx Pharmaceuticals, a,privately-held biopharmace...alization of compounds to treat endocrine, metabol...hat it has initiated a second,Phase 3 clinical tri...,s,estrogen-free oral therapy in development for t...
(Date:9/4/2008)...Remain on Schedule with Two Abstracts Accepted for... in November 2008, BRIDGEWATER, N.J., Sept. 4 /PR...cialty pharmaceutical company focused on the treat...y announced the appointment of,Peter L. Garrambone... Garrambone,s career includes more than 50 pharmac...
(Date:9/3/2008)... up results from chronically infected Hepatitis C,... obtained earlier in 2008, - Study is the first ... antiviral effect of therapeutic Hepatitis C...upport move into a second generation, vaccine for...hrough TLR activatio...
(Date:9/3/2008)...ny to Discuss Phase 3 Plans with FDA, PRINCETON, ...Inc.,announced today that it successfully complet...he company,s new, innovative low-dose, once-weekly... by its internal product,code AG-200-15. The Phase...,primary endpoint of ovulation suppression, cycle ...
Breaking Medicine Technology:QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome 2QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome 3Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials 2Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 2Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 3Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 4Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 2Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 3Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 4Male kidneys for men only 3F 23584 1Male kidneys for men only 3F 23584 2U M study 3A Herceptin targets breast cancer stem cells 3963 1U M study 3A Herceptin targets breast cancer stem cells 3963 2Big brains arose twice in higher primates 3959 1Big brains arose twice in higher primates 3959 2ACS Forum to Showcase Innovative Healthcare Model for European Union 23578 1ACS Forum to Showcase Innovative Healthcare Model for European Union 23578 2ACS Forum to Showcase Innovative Healthcare Model for European Union 23578 3
...AILEA, Hawaii and SUNNYVALE, Calif., June 27, 2007...ay announced,preliminary results from two open-lab...g the potential use of Xcytrin(R),(motexafin gadol...date, in combination with Alimta(R) (pemetrexed) a...a second-line treatment,for patients with non-smal...
...N DIEGO--(BUSINESS WIRE)--Jun 27, 2007 - The Unive...ed the following study and,press release, "Scienti...t Tissue," June 15, 2007, Science Daily: "Research...cine have successfully,isolated and cultured human...sue, suggesting that they have found another impor...
Other Medicine Technology:Pharmacyclics Announces Interim Results From Two Ongoing Phase 2,Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat,Recurrent Non-Small Cell Lung Cancer 2Pharmacyclics Announces Interim Results From Two Ongoing Phase 2,Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat,Recurrent Non-Small Cell Lung Cancer 3Pharmacyclics Announces Interim Results From Two Ongoing Phase 2,Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat,Recurrent Non-Small Cell Lung Cancer 4Pharmacyclics Announces Interim Results From Two Ongoing Phase 2,Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat,Recurrent Non-Small Cell Lung Cancer 5Bio-Matrix Scientific's Dr. O'Neill Sees University of Pittsburgh's,Published Study on Culture Blood-Forming Stem Cells from Human Fat,Tissue as Supporting Near Term Benefits of Banking Adipose (Fat),Derived Stem Cells 2Bio-Matrix Scientific's Dr. O'Neill Sees University of Pittsburgh's,Published Study on Culture Blood-Forming Stem Cells from Human Fat,Tissue as Supporting Near Term Benefits of Banking Adipose (Fat),Derived Stem Cells 3
High sensitive, specific one step immunochromatographic assay for human infectious disease
Span Diagnostics Limited
Malaria (P. fal.) Ag Rapid Test
OptiMAL is a malaria test, for diagnosis and therapy control of an infection by Plasmodium species (Malaria).
Medicine Products: